Natural Source
The below-ground biology of the blushwood tree shapes its growth and the chemistry of its seeds. A look at root structure, soil interaction, and rhizosphere ecology in Fontainea picrosperma.
Human Trials
RECIST 1.1 is the standard framework for measuring tumour response in clinical trials. Here is how it applies — and where it falls short — for intratumoural agents like tigilanol tiglate.
Mechanism of Action
cGAS-STING is the innate immune sensor that detects cytosolic DNA. Where does it fit in the picture of how EBC-46 and tigilanol tiglate trigger antitumour responses?
Regulatory
South Korea's MFDS uses three distinct categories for botanical products: Health Functional Foods, Korean traditional medicines, and general foods. Where would blushwood berry extract fit?
Consumer Reports
Tinctures and capsules deliver the same extract but in different ways. Here is what user reports and basic pharmacology say about choosing between them.
Botany
Fontainea picrosperma is dioecious — male and female flowers occur on separate trees. Here is what is known about its pollinators and seed set.
Human Trials
Imaging endpoints — particularly contrast-enhanced MRI — have become important in tigilanol tiglate trials. Here is how MRI is being used as a response biomarker.
Mechanism of Action
Tigilanol tiglate's mechanism extends beyond PKC activation. It engages innate immune pattern recognition receptors. Here is what the literature shows.
Regulatory
Singapore's Health Sciences Authority regulates health supplements under a notification framework. Here is how that affects EBC-46 supplement category imports.
Consumer Reports / Supplement
A neutral overview of how users describe pairing blushwood berry extract supplements with meals — fasted, with food, or with specific dietary fats — and how suppliers frame the question.
Natural Source / Botany
How alternate leaf arrangement, branch angles and rainforest understorey light shape canopy architecture in Fontainea picrosperma, the source of blushwood berries used in EBC-46 supplements.
Human Trials
How pharmacokinetic sampling, plasma assays and exposure-response modelling are designed for intratumourally administered EBC-46 / tigilanol tiglate Phase I clinical trials.